Results 1 to 10 of about 8,257 (246)

Infantile epileptic spasms syndrome: an etiologic study of 361 patients with infantile epileptic spasms syndrome [PDF]

open access: yesFrontiers in Pediatrics
IntroductionInfantile Epileptic Spasms Syndrome (IESS) typically has a profound impact on the neurodevelopment of patients. The study on IESS indicates possible geographical variation in etiology and a lack of data from China.
Baomin Li, Li Baomin
exaly   +6 more sources

Different pharmacoresistance of focal epileptic spasms, generalized epileptic spasms, and generalized epileptic spasms combined with focal seizures [PDF]

open access: yesEpilepsia Open, 2022
Objective Among standard treatments for infantile spasms, adrenocorticotropic hormone (ACTH) is reported as the best treatment, but ACTH is ineffective in one‐half of the patients.
Yukitoshi Takahashi
exaly   +4 more sources

Electroclinical Features of Infantile Epileptic Spasms Syndrome [PDF]

open access: yesAnnals of Indian Academy of Neurology
Epileptic spasms are a unique, age-dependent manifestation of epilepsies in infancy and early childhood, commonly occurring as part of infantile epileptic spasms syndrome.
Gozde Erdemir, Ahsan N. Moosa
doaj   +4 more sources

Status Epilepticus Manifested as Continuous Epileptic Spasms [PDF]

open access: yesFrontiers in Neurology, 2020
Objective: The etiology and outcome of status epilepticus with continuous epileptic spasms have not been fully understood; and only rare cases have been reported in the literature.
Jianxiang Liao   +12 more
doaj   +3 more sources

Decreased cerebrospinal fluid kynurenic acid in epileptic spasms: A biomarker of response to corticosteroids

open access: yesEBioMedicine, 2022
Summary: Background: Epileptic (previously infantile) spasms is the most common epileptic encephalopathy occurring during infancy and is frequently associated with abnormal neurodevelopmental outcomes.
Russell Dale   +2 more
exaly   +3 more sources

Treatment efficacy for infantile epileptic spasms syndrome in children with trisomy 21 [PDF]

open access: yesFrontiers in Pediatrics
BackgroundInfantile Epileptic Spasms Syndrome (IESS) is the most common epilepsy syndrome in children with trisomy 21. First-line standard treatments for IESS include adrenocorticotropic hormone (ACTH), oral corticosteroids, and vigabatrin.
Henry Chen   +13 more
doaj   +2 more sources

Infantile epileptic spasms syndrome: Mechanisms and therapeutic approaches [PDF]

open access: yesNeurotherapeutics
Infantile epileptic spasms syndrome (IESS) is a developmental and. epileptic encephalopathy with unique clinical and electrographic features, including seizure semiology (spasms), numerous and diverse etiologies spanning structural, genetic and metabolic
Carl E. Stafstrom
doaj   +2 more sources

IESS-FusionNet: Physiologically Inspired EEG-EMG Fusion with Linear Recurrent Attention for Infantile Epileptic Spasms Syndrome Detection [PDF]

open access: yesBioengineering
Infantile Epileptic Spasms Syndrome (IESS) is a devastating epileptic encephalopathy of infancy that carries a high risk of lifelong neurodevelopmental disability.
Junyuan Feng   +6 more
doaj   +2 more sources

Ketogenic diet for infantile epileptic spasms

open access: yesEpilepsia Open
Abstract Approximately half of all cases of Infantile Epileptic Spasms Syndrome (IESS) do not respond to vigabatrin and hormonal therapies. There is no clear consensus as to the second‐line therapy for IESS.
Morris H. Scantlebury   +3 more
openaire   +3 more sources

Timing the clinical onset of epileptic spasms in infantile epileptic spasms syndrome: A tertiary health center's experience. [PDF]

open access: yesEpilepsia
AbstractObjectiveLead time to treatment (clinical onset of epileptic spasms [ES] to initiation of appropriate treatment) is known to predict outcomes in infantile epileptic spasms syndrome (IESS). Timing the clinical onset of ES is crucial to establish lead time. We investigated how often ES onset could be established to the nearest week.
Hadjinicolaou A   +13 more
europepmc   +3 more sources

Home - About - Disclaimer - Privacy